Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

23,608 total articles

Edible Garden Wins Third New Walmart Fresh Herb Distribution Center Award, Accelerating Expansion Across the Eastern Midwest

Edible Garden Wins Third New Walmart Fresh Herb Distribution Center Award, Accelerating Expansion Across the Eastern Midwest

Edible Garden AG Incorporated announced it has secured a third Walmart distribution center for its fresh herb products, expanding its presence across the Eastern Midwest. This award enhances its regional retail reach, improves supply chain efficiency, and supports growth into higher-margin food and nutrition products. The company continues to lever…

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

Ocugen, Inc. announced that its investigational gene therapy OCU400 has received provisional approval and priority designation from the Longevity and Regenerative Therapies Board in The Bahamas. This approval enables Ocugen to offer OCU400 through an expanded access program with plans to treat the first patient within 90 days post full approval. OC…

Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

Legend Biotech Corp. reported five-year follow-up results from the CARTITUDE-2 study cohort A demonstrating that 50% of patients with relapsed/refractory multiple myeloma (RRMM) treated with a single infusion of CARVYKTI (ciltacabtagene autoleucel) remain alive and progression-free without maintenance therapy. The data reinforce the potential curat…

Reborn Coffee Enters into Strategic MOU with Visvita to Expand Global Franchise Supply Chain and Enter RTD Beverage Channels

Reborn Coffee Enters into Strategic MOU with Visvita to Expand Global Franchise Supply Chain and Enter RTD Beverage Channels

Reborn Coffee, Inc. has signed a non-binding Memorandum of Understanding with Visvita, a beverage and distribution company, to leverage Visvita’s US and Mexico distribution infrastructure for expanding Reborn's global franchise supply chain and launching a co-branded ready-to-drink (RTD) beverage lineup. The partnership aims to improve supply chain…

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

Fate Therapeutics announced a $15 million grant award from the California Institute for Regenerative Medicine (CIRM) to support its Phase 2 RECLAIM-LN trial, investigating FT819, an off-the-shelf CAR T-cell therapy for patients with refractory moderate-to-severe lupus nephritis. The therapy aims to offer durable B cell depletion, potentially improv…

FactSet Appoints Marcel Prins to Board of Directors

FactSet Appoints Marcel Prins to Board of Directors

FactSet has appointed Marcel Prins, an experienced leader in operations, technology, and asset management, to its Board of Directors. Prins's background in digital transformation and data governance at major European asset managers is expected to enhance FactSet's strategic initiatives in AI and financial intelligence solutions.

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting

C4 Therapeutics (Nasdaq: CCCC) presented encouraging biomarker data from their Phase 1 trial of cemsidomide with dexamethasone and Phase 1b trial combining cemsidomide with elranatamab in relapsed/refractory multiple myeloma patients. The data showed robust T-cell activation, enhanced immune response, and safety at initial dose levels, supporting c…

VEON Capital Markets Day 2026

VEON Capital Markets Day 2026

VEON Ltd., a Nasdaq-listed global digital operator, announced its upcoming Capital Markets Day event to be held on November 16, 2026, in New York City. The event will include presentations on VEON's strategic priorities, business performance, outlook, and long-term value creation. Investors and analysts can attend in person or virtually via webcast…

Kyivstar Capital Markets Day 2026

Kyivstar Capital Markets Day 2026

Kyivstar Group Ltd., the leading Ukrainian digital operator and first Ukrainian company listed on Nasdaq, will hold its Capital Markets Day on November 17, 2026, at Nasdaq MarketSite in New York. The event will include presentations on company strategy, performance, and future outlook, and will be accessible in person or via webcast.

ArcelorMittal announces that it is unable to safely and sustainably restart operations at ArcelorMittal Kryvyi Rih following multiple recent missile strikes

ArcelorMittal announces that it is unable to safely and sustainably restart operations at ArcelorMittal Kryvyi Rih following multiple recent missile strikes

ArcelorMittal announced it cannot safely and sustainably resume operations at its Kryvyi Rih steel plant in Ukraine due to multiple recent missile attacks that caused fatalities, injuries, and severe damage to the facility. The company plans to preserve infrastructure until peace returns but expects a non-cash impairment charge of approximately $1 …

Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment

Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment

Alamar Biosciences announced publication of a pivotal study in The Lancet Neurology demonstrating the use of its NULISAseq CNS 120 panel to track diverse plasma biomarkers in Alzheimer's patients treated with anti-amyloid antibody therapy (lecanemab). The study highlights distinct biological pathways involved in amyloid clearance versus cognitive d…

UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D. to Its Board of Directors

UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D. to Its Board of Directors

Clover Health announced the addition of former U.S. Senator Robert Torricelli and Dr. Brian J. Miller to its Board of Directors. These appointments fill existing vacancies and bring valuable expertise in federal healthcare policy, Medicare Advantage, clinical medicine, and healthcare technology to the board. The move is expected to support Clover H…

PEDEVCO to Participate in Upcoming Investor Conferences

PEDEVCO to Participate in Upcoming Investor Conferences

PEDEVCO Corp., a publicly traded energy company focusing on oil and gas asset acquisition and development in the Rocky Mountain region, announced that its Interim President and CEO, along with its CFO, will be participating in two virtual investor conferences hosted by Lytham Partners and Noble Capital Markets. These presentations aim to update inv…

22nd Century Group Urges Policymakers and FDA to Enact and Implement the Reduced Nicotine Content Standard, Citing Years Without a Final Rule

22nd Century Group Urges Policymakers and FDA to Enact and Implement the Reduced Nicotine Content Standard, Citing Years Without a Final Rule

22nd Century Group, Inc. calls on U.S. policymakers and the FDA to finalize and implement the proposed reduced nicotine content standard for combustible tobacco products, which has been pending for over a year. The company supports the administration's efforts to accelerate authorizations for vape and nicotine pouch products but stresses that nicot…

Battalion Oil to Release Investor Presentation on Sept. 30

Battalion Oil to Release Investor Presentation on Sept. 30

Battalion Oil Corporation plans to release an updated investor presentation on September 30, 2026, highlighting its corporate overview, operational updates, capital structure, liquidity, and future outlook. The company aims to maintain transparent communication with shareholders as it lays out its strategy for value creation.

Ormat Selected for Approximately $35 Million in U.S. Department of Energy Funding to Advance EGS and Hydrothermal Development

Ormat Selected for Approximately $35 Million in U.S. Department of Energy Funding to Advance EGS and Hydrothermal Development

Ormat Technologies announced it has been selected for approximately $35 million in funding from the U.S. Department of Energy to advance two geothermal projects: an Enhanced Geothermal Systems project at Dixie Valley, Nevada, and a hydrothermal development project at Cove Fort, Utah. These awards aim to support innovative geothermal technologies an…

Waldencast plc Files Form 25 to Voluntary Delist from Nasdaq and Deregister its Securities under the Exchange Act

Waldencast plc Files Form 25 to Voluntary Delist from Nasdaq and Deregister its Securities under the Exchange Act

Waldencast plc filed Form 25 with the SEC to voluntarily delist its Class A Ordinary Shares and Warrants from Nasdaq and to deregister these securities under the Exchange Act. The last trading day on Nasdaq is anticipated to be October 2, 2026, and deregistration will become effective approximately 90 days post-filing. The company plans to suspend …